Navigation Links
Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
Date:10/27/2008

eillance data examining ceftaroline in vitro activity against isolates from cSSSI and CAP. Ceftaroline was highly active against over 1,500 gram-positive pathogens isolated from cSSSI in the US and Europe, including methicillin-resistant Staphylococcus aureus (MRSA) and fluoroquinolone-resistant streptococci, thus, providing strong support for the use of this agent in the treatment of complicated skin infections. Furthermore, it was found to be highly active against more than 500 community-acquired respiratory tract clinical isolates, including difficult-to-treat antibiotic-resistant strains.(2,3)

--Activities of ceftaroline, ceftobiprole, and cethromycin against multi-drug-resistant (MDR) Streptococcus pneumoniae isolates from Canadian Bacterial Surveillance Network (CBSN) (Poster C1-3843)(4)

Dr. D. Low and colleagues from the Canadian Bacterial Surveillance Network report that three new antibiotics, cethromycin, ceftaroline, and ceftobiprole, have greater in vitro activity against MDRSP than ceftriaxone. Ceftaroline was eight-fold more active than ceftriaxone and four-fold more active than ceftobiprole against these resistant pathogens, supporting its use in potentially life-threatening infections caused by these bacteria.(4)

--In vitro activity of ceftaroline (CPT) vs. vancomycin (VM) against MRSA and hVISA strains in a pharmacokinetic/pharmacodynamic (PK/PD) model (Poster A-979)(5)

--In vitro activity of ceftaroline against CA-MRSA, VISA, VRSA and daptomycin-non-susceptible Staphylococcus aureus (DNSSA) (Poster C1-162)(6)

Dr. C. Vidaillac and colleagues used an in vitro model system to compare the activity of ceftaroline with vancomycin. Ceftaroline was more active against a S. aureus strain with intermediate susceptibility to vancomycin and showed similar or superior activity against MRSA, suggesting that it may provide a new option for the treatment of antibiotic-resistant S. aureus.(5) In support, Dr. L. Saravolatz and colle
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
2. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
3. Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society
4. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
5. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Kuvan Receives Positive Opinion From CHMP for European Approval
9. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
10. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
11. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Rockville, MD (PRWEB) September 17, 2014 ... Small Business Innovation Research (SBIR) grant to support the ... award will provide ITI with approximately $255,000 over one ... a leading cause of food allergy, affect over one ... anaphylaxis behind peanut allergy. Tree nut exposure is also ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia Therapeutics, ... data from a study of the cost and predictability ... 50 th Annual Meeting of the European Association ... session today, Christian Frois , Ph.D., of Analysis ... series of planned Intarcia-sponsored, retrospective studies to characterize the ...
(Date:9/17/2014)... LAUDERDALE, Fla. , Sept. 17, 2014 Alternative ... an agreement to form a Special Purpose Vehicle in partnership ... based Jatropha centric agro energy company. The SPV shall be ... registered entity with AFAI as majority shareholder. The SPV shall ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... DIEGO, March 16 Prometheus Laboratories Inc., a specialty ... received New York State approval for PROMETHEUS(R) IBS Diagnostic, ... syndrome (IBS). This novel test incorporates 10 biomarkers, ... algorithm to help physicians diagnose patients with IBS."One out ...
... N.J., March 16 DOR BioPharma, Inc. (OTC Bulletin ... it has appointed Gregg Lapointe, CPA, MBA, to its ... Executive Officer of Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau), a company ... patients with rare diseases. Sigma-Tau is DOR,s North American ...
... experts will address the benefits of rigorous early phase ... American Society for Clinical Pharmacology and Therapeutics (ASCPT), to ... Harbor, Maryland from March 18 - 21, 2009. The ... be to help biopharmaceutical companies understand best practice approaches ...
Cached Biology Technology:Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome 2DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 2DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 3DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 4PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 2PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 3PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 4
(Date:9/17/2014)... Transmission of bacterial infections, including MRSA and MSSA ... microscopic bumps that mimic the scaly surface of ... open access journal Antimicrobial Resistance and Infection ... different materials prevented the spread of human disease ... named Sharklet, is an arrangement of ridges formulated ...
(Date:9/16/2014)... North American Menopause Society (NAMS) has published its ... midlife womenon everything from hot flashes to heart ... Society Recommendations for Clinical Care of Midlife Women," ... Menopause . This is the first, comprehensive ... midlife women freely available to all clinicians who ...
(Date:9/16/2014)... 36 Pit Fire began on September 13, 2014. The ... It is currently over 2,300 acres in size and is ... 36 Pit Fire was calm Monday night due to higher ... an anchor point and beginning to construct a fireline on ... following resources are working on the fire: , 7 20-person ...
Breaking Biology News(10 mins):Sharks' skin has teeth in the fight against hospital superbugs 2
... A new report demonstrates how a sensitive imaging ... bacteria in chronic infections. Listeria monocytogenes is ... illness and death. Listeria outbreaks recently claimed twenty ... most common cause of bacterial meningitis in newborns, and ...
... for simple taskswould have smiled at one of leptin,s mechanisms ... fat-derived hormone enlists the sympathetic nervous system to prevent bone-making ... discharge insulin. The study will appear online December 22, ... print issue of The Journal of Cell Biology ...
... the latest American Chemical Society (ACS) News Service ... journals and Chemical & Engineering News.,Please credit the ... the source for this information. ALL CONTENT ... is embargoed for 9 a. m., Eastern Time, ...
Cached Biology News:New research lights up chronic bacterial infection inside bone 2Leptin's long-distance call to the pancreas 2American Chemical Society's Weekly PressPac -- Dec. 17, 2008 2American Chemical Society's Weekly PressPac -- Dec. 17, 2008 3American Chemical Society's Weekly PressPac -- Dec. 17, 2008 4American Chemical Society's Weekly PressPac -- Dec. 17, 2008 5American Chemical Society's Weekly PressPac -- Dec. 17, 2008 6American Chemical Society's Weekly PressPac -- Dec. 17, 2008 7American Chemical Society's Weekly PressPac -- Dec. 17, 2008 8
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... are derived from frozen embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... are large (3-5mm in diameter) in comparison ...
Biology Products: